STOCK TITAN

Zone Healthcare and Farallon disclose 7.6% and 9.7% holdings in Beta Bionics

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

This Schedule 13G/A discloses significant beneficial ownership positions in Beta Bionics common stock by Zone Healthcare, multiple Farallon-managed funds, their management company and numerous Farallon individual reporting persons. Zone Healthcare Holdings, LLC and Farallon Capital Management, L.L.C. are each reported with shared voting and dispositive power over 3,277,220 shares (7.6% of the class). Several Farallon funds disclose smaller direct holdings (examples include 166,877 and 380,597 shares). A set of Farallon individual reporting persons are each shown with an aggregate beneficial amount of 4,203,920 shares (9.7% of the class), and the filing states these individuals may be deemed beneficial owners based on their roles while disclaiming beneficial ownership.

The filing is submitted pursuant to the passive investor provision of the rules and includes a certification that the securities were not acquired to change or influence control. The Reporting Persons indicate they neither affirm nor disclaim the existence of a group among them and include standard power-of-attorney signatures for the reporting entities and individuals.

Positive

  • Zone Healthcare and Farallon report shared voting/dispositive power over 3,277,220 shares (7.6% of class)
  • Farallon individual reporting persons are disclosed with an aggregate beneficial amount of 4,203,920 shares (9.7% of class)
  • Filing made under the passive investor rule (Section 13d-1(c)), with a certification that shares were not acquired to change or influence control

Negative

  • None.

Insights

TL;DR: Farallon-related entities report meaningful passive stakes—Zone/Farallon show 7.6% via ZHH LLC and individuals listed at 9.7% aggregate.

The Schedule 13G/A documents material passive positions in Beta Bionics by multiple Farallon-managed vehicles and affiliated individuals. The clear presentation of shared voting and dispositive power for 3,277,220 shares (7.6%) via Zone/Farallon entities and the listing of 4,203,920 shares (9.7%) under individual reporting persons are the most consequential data points for holders and observers. Filing under the passive investor rule signals no current intent to influence control, which limits immediate governance implications but identifies concentrated ownership that investors should monitor through subsequent filings.

TL;DR: Ownership concentrations are material but declared passive; governance impact is currently limited by disclaimers and the 13G filing route.

The disclosure shows multiple affiliated entities and senior managers connected to the same investment adviser structure, with reporting lines that could create de facto coordination despite legal disclaimers. The filing explicitly states the Reporting Persons "neither disclaim nor affirm the existence of a group," and individual managers are listed as having potential investment discretion. Because this is a Schedule 13G/A filed under the passive-investor provision, the stated posture is non-control; however, the aggregated percentages—especially the 9.7% figure noted for individual reporting persons—represent a meaningful ownership block from a governance perspective if holdings were to change or be recharacterized.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Zone Healthcare Holdings, LLC
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its Manager
Date:08/13/2025
Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:08/13/2025
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member of its General Partner
Date:08/13/2025
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager of its General Partner
Date:08/13/2025
Farallon Capital Management, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member
Date:08/13/2025
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Managing Member
Date:08/13/2025
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:08/13/2025
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, Manager
Date:08/13/2025
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:08/13/2025
Fried, Richard B
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Patel, Rajiv A.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Seybold, William
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn, as attorney-in-fact
Date:08/13/2025

FAQ

Who filed the Schedule 13G/A for Beta Bionics (BBNX)?

The statement is filed by Zone Healthcare Holdings, LLC; multiple Farallon-managed funds and entities; Farallon Capital Management, L.L.C.; Farallon Partners, L.L.C.; related general partners; and named Farallon individual reporting persons.

How many shares does Zone Healthcare/Farallon report owning in Beta Bionics (BBNX)?

Zone Healthcare Holdings, LLC and related Farallon reporting entities are shown with shared voting and dispositive power over 3,277,220 shares, representing 7.6% of the class as reported on the cover pages.

What is the 4,203,920 shares figure listed in the filing for BBNX?

Several Farallon individual reporting persons are each listed with an aggregate beneficial amount of 4,203,920 shares, representing 9.7% of the class as shown on their respective cover pages.

Was this filing made as a passive investor under Schedule 13G?

Yes. The Reporting Persons state the Schedule is filed pursuant to the passive investor rule and include a certification that the securities were not acquired to change or influence control.

Do the Reporting Persons claim control or a group agreement in this filing for BBNX?

The filing states the Reporting Persons "neither disclaim nor affirm the existence of a group among them," and they assert the positions are not held to change or influence control.
Beta Bionics, Inc.

NASDAQ:BBNX

BBNX Rankings

BBNX Latest News

BBNX Latest SEC Filings

BBNX Stock Data

1.37B
39.16M
6.49%
104.92%
7.16%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
IRVINE